We recently published an article titled Why Traders Flocked to These 10 Stocks on Monday.In this article, we are going to take a look at where CG Oncology, Inc. (NASDAQ:CGON) stands against the other stocks.

The stock market kicked off the trading week on a mixed note, with two major indices ending in the green, as investors continued to digest more corporate earnings results.

Among the bellwether indices, only the Nasdaq ended in the red, dropping 0.10 percent. In contrast, the Dow Jones grew by 0.28 percent and the S&P 500 inched up by 0.06 percent.

Meanwhile, 10 companies mirrored a broader market optimism, as investors snapped up shares ahead of their first-quarter earnings performance in the next few days.

To come up with the list, we considered only the companies with a $2-billion market capitalization and $5-million trading volume.

A research doctor, looking intently at their microscope as they try to decipher the mysteries of immuno-oncology.

CG Oncology, Inc. (NASDAQ:CGON)

CG Oncology, Inc. (NASDAQ:CGON) grew its share prices for a fifth straight day on Monday, surging 25.03 percent to end at $27.97 apiece as investors cheered the promising results of its bladder cancer treatment that could rival Johnson & Johnson’s.

Following a two-year study, CG Oncology, Inc. (NASDAQ:CGON) said that cretostimogene grenadenorepvec—its investigational monotherapy for high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to BCG treatment— reported a robust 42.3 percent response rate and 97.3 percent non-progression to muscle-invasive disease.

Additionally, 91.6 percent of the enrollees retained their ability to avoid cystectomy.

The treatment, which could rival Johnson & Johnson’s own bladder cancer treatment, demonstrated a high degree of safety without adverse effects reported.

Following the announcement, Cantor Fitzgerald reiterated its Overweight rating for CG Oncology, Inc. (NASDAQ:CGON) alongside a price target of $75, or a 168-percent upside from its latest closing price.

Overall CGON ranks 2nd on our list of the best performing stocks on Monday. While we acknowledge the potential of CGON as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than CGON but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

Story Continues

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.

View Comments